CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease: Grenoble, France Friday, April 4, 2025, 12:00 Hrs [IST] Averoa, a biopharmaceutical c ...

ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...

Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, today announces a positive opinion from the European Medicines Agency (EMA)’s Committee for ...

Last week, the Medicines and Healthcare products Regulatory Agency hosted a landmark event in Westminster, London, to ...